CA-TRILINK-BIOTECH
TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418722567/en/
TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)
Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, increased mRNA capacity (1g to >100g per batch), comprehensive in-house analytical services, and laboratory space for on-site quality control testing. The manufacturing suites are outfitted with state-of-the-art equipment and ready to onboard clients with late-phase manufacturing needs.
“This facility is expected to help move the needle for life-saving breakthroughs in mRNA-therapeutics,” explained Kevin Lynch, Vice President & General Manager of TriLink’s GMP Operations. “The high-quality manufacture of mRNA drug substances is critical to ensuring the safety and efficacy of this new class of medicines for patients.”
Company and site leadership and industry guests gathered on April 17 to celebrate the facility’s grand opening with a ribbon cutting, expert-led panel discussion, and site tours – all centered around a core theme: Building the Future of mRNA. The thought-provoking panel included insights on the mRNA regulatory landscape, manufacturing evolution, and next-generation tools.
TriLink has reliably delivered GMP services to drug developers since the debut of its first cGMP facility in 2015. Since then, the company’s dedicated team of scientists has provided over 1,000 clients with custom mRNA synthesis, supported 350+ programs in biopharma development pipelines, and delivered over 100 GMP mRNA manufacturing batches.
“TriLink’s depth of industry experience – which spans over 25 years – coupled with its capabilities makes for an unmatched partner,” shared Drew Burch, President of Nucleic Acid Production. “This new facility codifies our commitment to advancing the field by playing a key role in the development of mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.”
In addition to CDMO services and unique mRNA, oligonucleotide, NTP, and plasmid production capabilities, TriLink has developed the award-winning CleanCap® mRNA capping technology used in the majority of approved COVID-19 mRNA and saRNA vaccines, adding momentum to the rapidly growing field.
To learn more about TriLink’s products and services, visit trilinkbiotech.com.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the expectation that the facility will help advance the field of mRNA-based medicine and will help move the needle for life-saving breakthroughs, constitute forward-looking statements identified by words like “expect,” “estimate,” “may,” “soon,” “nears,” “slated,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, operational risks and competition. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K, as well as other reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418722567/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 16:30:00 CET | Press release
The agreement builds on Nexo’s long-term approach to partnerships with established global sports institutions. Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title spons
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release
At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release
Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom